Targeted Antibody Therapy Offers Long-Lasting Neuropathic Pain Relief

Nav1.7 Antibodies and Mechanism of Action

Neuropathic pain occurs when damaged nerves generate abnormal electrical signals in the absence of fresh injuries. To counter this without dulling necessary protective reflexes, the research team focused on Nav1.7, a voltage-gated sodium channel expressed in sensory neurons that transmits pain signals. According to Dr. Uta, Nav1.7 plays a critical role in sensing and transmitting these impulses.

The investigators engineered humanized antibodies capable of recognizing and binding to Nav1.7. In cell-based tests, these antibodies selectively inhibited the channel’s function and reduced the electrical activity of pain-signaling nerve cells. Specifically, variants designated as Clone1 and S-151128 demonstrated strong binding affinities, exhibiting at least 650-fold and 1,300-fold selectivity, respectively, over other tested sodium channel subtypes.

Efficacy in Rat Models of Nerve Injury

To test how the treatment performs in living systems, researchers administered the antibodies intravenously to rats with partial sciatic nerve ligation, a standard laboratory model for neuropathic pain. This systemic delivery route avoided the need for local injections directly into nerves or the spinal cord. Both tested antibodies successfully reduced animal sensitivity to mechanical stimulation in a dose-dependent manner, according to the study.

At specific doses, the analgesic performance matched that of pregabalin. Crucially, the antibodies maintained stronger pain-relieving effects than pregabalin 96 hours post-treatment. Examination of the central nervous system revealed that spinal dorsal horn neurons in injured rats showed reduced spontaneous activity and lower responses to mechanical touch following antibody treatment. Furthermore, researchers noted fewer dorsal root ganglion neurons displaying mechanically induced phosphorylation of extracellular signal-regulated kinase, a standard biological marker of nerve cell activation.

Preserving Normal Sensation and Motor Function

A primary hurdle in treating nerve damage has been the risk of blocking normal, protective pain sensations that warn the body of acute harm. To address this risk, the team tested the antibodies on healthy animals without nerve injuries. The treatments did not significantly alter the animals’ physical responses to mechanical stimulation.

Motor function was evaluated using a rotating-rod test. While the comparison medication pregabalin impaired motor performance at the tested dose, the anti-Nav1.7 antibodies caused no significant motor deficits. “Targeting Nav1.7 could help silence abnormal pain signals while preserving normal protective pain sensation,” Dr. Uta notes.

Current Limitations and Clinical Progress

Because the investigation remains in the preclinical phase, scientists faced limitations in accurately measuring the exact concentration of antibodies that reached the injured nerve tissues. Additionally, the team evaluated the treatment using only a single neuropathic pain model, underscoring the necessity for future studies to determine if these findings replicate across other injury models.

Despite these caveats, the research marks a tangible step forward. The study authors report that one of the evaluated antibodies, S-151128, has already advanced into clinical trials, moving closer to establishing whether these animal-model observations can translate into safe and effective treatments for human patients.

What are your thoughts on targeting ion channels for chronic pain management? Share your insights or questions in the comments below, and subscribe to our newsletter for the latest updates in biomedical research.